Voyager Therapeutics is trading 5.07% down at $2.15; biotech-sector weakness is relevant context, but no company-specific cause has been confirmed for the October 13 decline.
- The XBI sector was down 2.01% during the regular session, though that does not fully explain Voyager Therapeutics’ larger decline.
- A report said Sanofi returned rights to two neurology gene therapies, but did not establish this as the reason for the share move.